外科治疗胃癌肝转移疗效分析

目的探讨外科治疗胃癌肝转移的方法与疗效。方法1996年1月至2003年12月间行外科治疗的胃癌肝转移患者25例，17例为同时性肝转移，8例为术后发现的异时性肝转移。其中单转移灶15例，多转移灶10例。行不规则肝切除16例，左外叶切除4例，左叶切除3例，右叶切除2例，术后行肝动脉灌注化疗9例，肝动脉化疗栓塞16例。结果1例同时性肝切除患者术后死于肺部感染、成人呼吸窘迫综合征，余24例均获随访，中位时间25(7—60)个月。胃癌肝转移灶切除后1、3年生存率为68．5％和29．8％，原发癌浸润表浅、淋巴结转移少、单转移灶、异时性转移及转移灶有包膜是影响生存率的有利因素。结论同时及异时性胃癌肝转移可经外科手术切除肝转移灶，但应注意手术指征的把握。     

胃癌肝转移外科治疗的临床分析

目的 评价胃癌肝转移的外科治疗效果及病理因素对其预后的影响。方法 本组834例胃癌患者中共有91例诊断为肝转移，其中79例为同时性肝转移，12例术后发现异时转移，共21例行胃癌肝转移灶切除术。结果 胃癌肝转移灶切除后1年、3年生存率分别为69％、30％。单转移灶及异时性转移是其有利的预后因素。13例肝转移灶有假包膜形成。结论 单转移灶及异时转移、肿瘤假包膜形成预示胃癌肝转移切除患者有较好的预后。     

胃癌肝转移患者的手术治疗及预后分析

目的探讨胃癌肝转移患者手术治疗的指征和效果。方法回顾性分析我院1995年9月至2002年5月间经手术治疗的43例胃癌肝转移患者的临床资料。结果全组肝转移程度与患者性别、年龄、肿瘤侵犯深度、分化程度及有无淋巴结转移无相关关系(P>0.05)。异时性肝转移行肝切除4例,中位生存时间为35.0个月,预后明显优于同时性肝转移肝切除患者(中位生存时间10.0个月)(P=0.0233)。同时性肝转移组中,单纯胃切除32例,中位生存时间6.0个月;胃加肝切除7例,中位生存时间10.0个月,两组差异无统计学意义(P=0.2799)。不同肝转移程度姑息性胃切除术后生存时间比较,H1、H2和H33组分别为7.5、6.0和4.0个月,差异具有统计学意义(P=0.0007)。结论异时性胃癌肝转移患者肝切除术后预后良好,应争取积极手术切除;胃癌肝转移患者同期行胃加肝切除生存率未见明显改善;H3肝转移患者姑息性胃切除预后不佳。     

胃癌同时性肝转移手术治疗效果分析

目的评价胃癌同时性肝转移外科效果。方法回顾性分析2005～2017年间就诊于安徽医科大学第一附属医院行手术治疗的40例胃癌同时性肝转移患者,所有患者均行胃原发灶D2切除,根据肝脏转移灶是否行R0切除,分为A组肝脏转移灶切除(20例)与B组肝脏转移灶未切除(20例),比较两组临床资料及术后生存情况。结果两组术后并发症发生率未见明显差异(P=1.000),A组中位生存时间为11月(95%CI 8.809～13.191)明显高于B组中位生存时间为5月(95%CI 2.078～7.922),P=0.009。A组术后6月、1年、2年、3年生存率均好于B组,但在术后6月(P=0.006)、术后1年比较差距有统计意义(P=0.047),术后2年、3年生存率差异无统计学意义(P0.05)。结论胃癌同时性肝转移患者,行胃癌D2切除联合肝脏转移灶R0切除,可延长患者生存期,且不增加术后并发症发生几率,具有良好的临床治疗效果。     

组织因子对SGC-7901 L2亚系胃癌细胞肝转移能力的影响

肝转移是影响胃癌预后的重要因素.Okano等[1]报道90例胃癌肝转移患者(同时性肝转移78例,异时性肝转移12例)中仅19例有条件行肝转移灶切除术,该19例患者1年和3年生存率分别为77%和34%.Hiratsuka等[2]报道胃癌肝转移患者中有40%合并腹膜转移,60%转移灶已累及肝左、右叶,仅10%有条件行B级治愈性切除术.本研究应用组织因子cDNA转染高转移能力的SGC-7901 L2亚系胃癌细胞,建它裸鼠原位种植肝转移动物模型,观察转染组织因子cDNA的SGC-7901 L2亚系细胞肝转移灶形成能力的变化,旨在探讨组织因子对胃癌细胞肝转移能力的影响.     

6669例结直肠癌同时陛和异时性肝转移患者不同治疗策略的预后分析

目的 评价结直肠癌肝转移不同类型及治疗策略对肝转移患者生存的影响.方法 回顾分析复旦大学附属中山医院2000年1月1日至2008年6月31日收治的669例结直肠癌肝转移患者的病例资料.结果 本组患者同时性肝转移379例,异时性[发生肝转移中位时间(21.0±19.6)个月]肝转移290例.患者性别、年龄和肠道原发病灶的部位两组差异无统计学意义(P>0.05);而肝转移灶特征(累及肝叶类型、病灶个数和病灶直径)和术前CEA、CA19-9水平两组差异有统计学意义(P<0.05).手术切除肝转移灶253例,其中同时性肝转移123例,异时性肝转移130例.以2008年10月31日为随访终点,随访率100%.同时性肝转移和异时性肝转移的中位生存时间分别为11和23个月(P<0.01).5年生存率分别为6.4%和11.4%(P<0.01):手术病例与各种非手术治疗(介入、化疗、射频、无水酒精注射和中医中药)病例的中位生存期分别为37个月和5～26个月(P<0.01);5年生存率分别为35.6%和0～3.6%(P<0.05).结论 手术治疗目前仍是结直肠癌肝转移的首选治疗措施;异时性肝转移患者生存率好于同时性肝转移.     

胃癌肝转移31例外科治疗体会

目的 探讨胃癌肝转移的外科治疗效果.方法 对我院1997年10月～2006年10月收治的原发性胃癌338例中伴肝转移的31例的临床资料进行回顾性分析.对其中施行同时性胃癌肝转移灶切除术(切除组)的19例和仅行胃癌根治术而未行肝转移灶切除术(未切除组)的12例的术后生存时间进行对比.结果 全组除1例术后死于肝功能衰竭外,其余30例均获得随访.胃癌肝转移灶切除术后1年、3年和5年生存率分别为83.3%、44.4%和33.3%;未切除组术后1年生存率为50.0%,3年及5年生存率为0.两组术后生存时间有显著性差异(P＜0.05).切除组病例中有68.4%在肿瘤和周围肝组织间形成纤维假膜.结论 假包膜形成是有利的预后因素.对于胃癌肝转移病人,特别是有假包膜形成者采用外科治疗预后更好.     

胃癌肝转移的手术治疗

目的 探讨胃癌肝转移行肝切除术的适应证及疗效。方法 对1990年1月至1999年11月间施行肝切除的24例胃癌肝转移患的临床资料进行回顾性分析。结果 本组同时性肝转移19例，异时性转移5例。共施行肝段叶切除8例，肝部分切除16例；19例同时性肝转移患均在肝切除的同时加行根治性胃切除术。术后并发肝昏迷死亡l例。手术死亡率为4．2％。全组22例获得随访。术后1年、3年和5年生存率分别为45．5％、18．2％和9．1％。生存分析显示，肝切除术后的生存率不仅与胃癌原发灶的分化程度、有无浆膜面浸润和淋巴结转移有关，而且与肝转移灶的数目及其在肝脏内的分布范围有关。结论对于胃癌孤立性肝转移患，其原发病灶可根治切除的应积极采用手术治疗，部分患可获长期生存。     

结直肠癌肝转移生存分析

目的分析结直肠癌肝转移病人的生存状况和相关影响因素。方法回顾性分析2000-2010年复旦大学附属中山医院收治的结直肠癌肝转移病人的临床资料、病理、治疗策略等情况,进行生存状况分析,并采用单因素和Cox比例风险回归模型等分析影响结直肠癌肝转移生存的相关因素。结果结直肠癌肝转移病人总体中位生存期22.0个月,5年存活率为16%,其中同时性肝转移为21.2个月和16%,异时性肝转移为30.1个月和23%,同时性肝转移组的存活率明显低于异时性肝转移组(P<0.01)。按治疗方式分组,手术组病人的中位生存期为49.8个月,5年存活率为37%,显著优于化疗组(22.2个月和0)、介入组(19.0个月和11%)、化疗+介入组(22.8个月和10%)、局部治疗组(28.5个月和0)。同时性肝转移、肠癌原发灶分化Ⅲ~Ⅳ级、肝转移灶≥4个、最大肝转移灶≥5cm和肝转移灶非手术处理是影响病人预后的独立危险因素。结论同时性肝转移病人生存期低于异时性肝转移。积极手术治疗可以改善病人存活率。扩大肝转移灶切除的适应证对病人存活率无显著影响。独立危险因素的评分体系可以评估病人的预后。     

大肠癌伴同时性肝转移126例临床分析

目的探讨大肠癌肝转移的临床特点与诊治效果。方法对126例大肠癌肝转移的临床资料进行回顾性总结分析。结果大肠癌同时性切除肝转移灶的手术切除率为17.5%(22/126),同时切除肝转移灶的病例1年生存率68.2%(15/22),3年生存率为40.9%(9/22),5年生存率为18.2%(4/22);而未切除肝转移灶的病例1年生存率为54.8%(57/104),3年生存率为16.3%(17/104),5年生存率为0%,两组生存率比较差异有显著性意义(P0.05)。结论手术同时切除肝转移灶为大肠癌伴同时性肝转移的首选治疗方法。     

Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma

Few patients with metastatic gastric cancer have disease that is amenable to curative surgery. Thus far, little is known about liver surgery for metastases arising from gastric adenocarcinoma and prognostic factors. Of 73 patients operated on between 1980 and 1999 for noncolorectal, non-neuroendocrine hepatic metastases, 15 underwent liver resection for gastric adenocarcinoma metastasis. Ten patients underwent synchronous hepatic resection and five underwent metachronous hepatic surgery after a median diseasefree interval of 10 months (range 6.1 to 47.3 months). None of the patients died within the first 30 days after surgery, and the in-hospital mortality rate was 6.7%. Among patients in the synchronous group, 26.7% experienced major complications mainly associated with gastric surgery. Overall median survival was 8.8 months (range 4 to 51 months); two patients survived more than 3 years. Univariate analysis reealed that the appearance of liver metastasis synchronous vs. metachronous), the distribution of liver metastases (unilobar vs. bilobar), and the primary tumor site (proximal vs. distal) were marginally signifiant predictive factors regarding overall survival. Because of its high morbidity, synchronous liver resecion for metastases originating from gastric adenocarcinoma is rarely followed by survival longer than 2 years. Primary tumor localization within the proximal third of the stomach and bilobar liver involvement appear to be predictive of poor outcome. On the other hand, curative resection of metachronous liver metastases may allow long-term survival in selected patients.     

Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate?

Background In cases of synchronous colorectal hepatic metastases, the primary colorectal cancer strongly influences on the metastases. Our treatment policy has been to conduct hepatic resection for the metastases at an interval of 3 months after colorectal resection. We examined the appropriateness of interval hepatic resection for synchronous hepatic metastasis. Materials and methods The subjects were 164 patients who underwent resection of hepatic metastasis of colorectal cancer (synchronous, 70 patients; metachronous, 94 patients). Background factors for hepatic metastasis and postoperative results were compared for synchronous and metachronous cases. Results The cumulative survival rate for 164 patients at 3, 5, and 10 years postoperatively was 71.9%, 51.8%, and 36.6%, and the post-resection recurrence rate in remnant livers was 26.8%. Interval resection for synchronous hepatic metastases was conducted in 49 cases after a mean interval of 131 days. No difference was seen in postoperative outcome between synchronous and metachronous cases. Conclusion The outcome was similarly favorable in cases of synchronous hepatic metastasis and in cases of metachronous metastasis. Delaying resection allows accurate understanding of the number and location of hepatic metastases, and is beneficial in determining candidates for surgery and in selecting surgical procedure.     

Hepatic Resection for Metastatic Tumors From Gastric Cancer

OBJECTIVE: To assess the surgical results and clinicopathologic features of hepatic metastases from gastric adenocarcinoma to identify patients with a better probability of survival. SUMMARY BACKGROUND DATA: Many studies have reported the benefit of hepatic resection for metastatic tumors from colorectal cancer. However, indications for a surgical approach for gastric adenocarcinoma involving the liver have not been clearly defined. METHODS: Ninety (11%) of 807 patients with primary gastric cancer were diagnosed with synchronous (n = 78) or metachronous (n = 12) hepatic metastases. Of these, 19 underwent 20 resections intended to cure the metastatic lesion in the liver. The clinicopathologic features of the hepatic metastases in, and the surgical results for, the 19 patients were analyzed. RESULTS: The actuarial 1-year, 3-year, and 5-year survival rates after hepatic resection were, respectively, 77%, 34%, and 34%, and three patients survived for more than 5 years after surgery. Solitary and metachronous metastases were significant determinants for a favorable prognosis after hepatic resection. Pathologically, a fibrous pseudocapsule between the tumor and surrounding hepatic parenchyma was found in 13 of the 19 patients (68%). The presence of a peritumoral fibrous pseudocapsule and a well-differentiated histologic type of metastatic nodule were significant prognostic factors. Factors associated with the primary lesion were not significant prognostic determinants in patients who underwent curative resection of the primary cancer. CONCLUSIONS: Solitary and metachronous metastases from gastric cancer should be treated by a surgical approach and confer a better prognosis. A new prognostic factor, the presence of a pseudocapsule, may be helpful in defining indications for postoperative adjuvant treatment.     

Outcome of hepatic resection for metastatic gastric cancer

The role of hepatic resection for metastatic gastric cancer is less well defined due to the tendency of gastric cancer to widely metastasize. The purpose of this study is to examine the beneficial effect of hepatic resection in patients with metastatic gastric cancer. The clinicopathologic features and long-term results of 11 patients who underwent hepatic resection for metastatic gastric cancer from January 1988 to December 1996 at Seoul National University Hospital were analyzed retrospectively. All resected hepatic metastases were solitary lesions. Among eight patients with synchronous hepatic metastases, one patient with early gastric cancer and lymph node metastases (T1N2M1) remained alive for 8 years 6 months after hepatic resection without recurrence. Among three patients with metachronous hepatic metastases, two patients with advanced gastric cancer and lymph node metastases (T3N2MO, T2N1MO at the initial operation, respectively) survived 8 years 6 months and 3 years after hepatic resection, respectively. Median survival times of synchronous and metachronous hepatic metastases were 13.0 and 74.3 months, respectively. In solitary hepatic metastatic lesions from gastric cancer, surgical resection should be considered as one of the treatment options.     

Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients

BACKGROUND: The justification for surgical resection of liver metastases from gastric cancer remains controversial. METHODS: Twenty-two patients who underwent 26 hepatectomies for liver metastases of gastric cancer between 1985 and 2001 were analyzed. Fifteen clinicopathologic factors were evaluated with univariate and multivariate analyses for survival after hepatic resection. RESULTS: The overall 1-year, 3-year, and 5-year survival rates after hepatectomy for gastric metastases were 73%, 38%, and 38%, respectively. Five patients survived for more than 3 years without recurrence, 3 of whom had synchronous metastases resected at the time of gastrectomy. The best results after surgical resection for liver metastases of gastric cancer were obtained with solitary metastases less than 5 cm in size. The number of liver metastases (solitary or multiple) was the only significant prognostic factor according to both univariate and multivariate analyses. CONCLUSION: Surgical resection for liver metastases of gastric cancer may be beneficial for patients with a solitary metastasis, whether it is synchronous or metachronous.     

胃癌并局限型肝转移同步切除九例报告

目的探讨同步切除治疗胃癌并局限型肝转移的临床效果。方法回顾性分析胃癌并局限型肝转移行同步切除的9例患者的临床资料。结果行根治性远端胃大部分切除术7例,根治性近端胃大部分切除术1例,根治性全胃切除1例;局部肝切除8例,左半肝切除1例。无手术死亡病例。术后生存期分别为9、12、12、13、21、24、30、37和62个月,平均生存24.3个月。术后6例再发残肝转移。死亡原因中,3例死于残肝转移,3例死于腹膜转移。结论对胃癌并局限型肝转移患者施行原发灶根治性切除和肝转移灶同步切除可有效地延长生命。